Scancell: Response to Press Speculation
Physiomics strengthens outlook with cost savings and pipeline growth
Physiomics (AIM: PYC) has provided a positive operational update, highlighting record commercial opportunities, cost savings and a clearer path towards profitability as the AIM-listed modelling and data science specialist executes
Avacta advances AVA6000 towards pivotal US trial
Avacta Therapeutics (AIM: AVCT) has secured a significant regulatory milestone after reaching an agreement with the US Food and Drug Administration on the pivotal trial design for its lead cancer
ImmuPharma highlights brain cancer potential for P140
ImmuPharma (AIM: IMM) has highlighted new academic research suggesting its lead drug candidate, P140, may have potential as a treatment for glioblastoma, one of the most aggressive and difficult-to-treat forms
Shareholders give overwhelming support to Avacta proposals
Avacta Group PLC announced that all resolutions were passed at its Annual General Meeting, with overwhelming shareholder support for each proposal.
Solvonis rises 13% on promising AUD treatment results
Solvonis Therapeutics (LON: SVNS) shares surged 13% in early trading after the company announced positive preclinical pharmacokinetic data for its lead Alcohol Use Disorder treatment candidate, SVN-002, marking an important
Avacta Extends Cash Runway as Clinical Pipeline Advances
Avacta Therapeutics (AIM: AVCT) has reported strong progress across its oncology pipeline in the first half of 2026, highlighting advances in both its clinical programmes and balance sheet ahead of
Genflow Biosciences to Showcase Longevity Gene Therapy Data at Major Industry Summit
Genflow Biosciences plc (LON: GENF) has been invited to present results from its SLAB (Sarcopenia and Longevity in Aged Beagles) study at the Animal Longevity Summit 2026, a specialist conference
Poolbeg Pharma (AIM: POLB) European patent granted for POLB 001 in CRS
Decision to grant European Patent received for POLB 001 in cancer immunotherapy-induced CRS Major milestone will provide IP protection in key European markets, strengthening global patent portfolio
MedPal AI Shares Jump 40% as UK Approves First Oral GLP-1 Weight Loss Treatment
Shares in MedPal AI plc (AIM: MPAL) surged 40% during Friday trading to a three-month high of around 4.35p after the company highlighted the UK approval of the first oral
Poolbeg Pharma PLC (AIM: POLB) Preclinical data posters presented at EHA Congress
Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress
£9m fundraising gives Avacta extra firepower for cancer pipeline
Avacta Therapeutics plc (AIM: AVCT) has strengthened its balance sheet after completing an oversubscribed £9 million equity fundraising, with proceeds earmarked primarily for reducing outstanding convertible bond debt and supporting